Concepedia

Tanyel Kiziltepe

TK

Statistics

Publications

51

Citations

5K

H-Index

34

Active since

2002

Affiliations

University of Notre Dame(Current)

Dana-Farber Cancer Institute

Harvard University

Massachusetts General Hospital

Massachusetts Institute of Technology

Tanyel Kiziltepe is an author at University of Notre Dame specializing in oncology, multiple myeloma treatment, and multiple myeloma therapy.

ORCID

Publications per year

2002–2020

51

Publications

51

Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system

Shiladitya Sengupta, David A. Eavarone, Ishan Capila et al. · Nature · 2005 · 943 citations

, , +16

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

Naoya Mimura, Mariateresa Fulciniti, Güllü Görgün et al. · Blood · 2012 · 435 citations · Full text

, , +9

Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

Laurence Catley, Ellen Weisberg, Tanyel Kiziltepe et al. · Blood · 2006 · 340 citations · Full text

, , +17

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

Yutaka Okawa, Teru Hideshima, Paul M. Steed et al. · Blood · 2008 · 209 citations · Full text

, , +16

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells <i>In vitro</i> and <i>In vivo</i>

Hiroshi Ikeda, Teru Hideshima, Mariateresa Fulciniti et al. · Clinical Cancer Research · 2009 · 204 citations · Full text

, , +14

1–5 of 51